Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
takeda.com

See what CB Insights has to offer

Investments

25

Portfolio Exits

9

Partners & Customers

10

Service Providers

1

About Takeda Pharmaceutical

Takeda Pharmaceutical (TYO: 4502) (NYSE: TAK) is a research-based, global pharmaceutical company. Takeda is committed to striving toward better health for patients worldwide through innovation in medicine.

Takeda Pharmaceutical Headquarter Location

2-1-1 Nihonbashihonmachi, Chuo-ku

Tokyo, 103-8668,

Japan

+81 (0)3 3278 2111

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Takeda Pharmaceutical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Takeda Pharmaceutical in 3 Expert Collections, including Poop Tech.

P

Poop Tech

114 items

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

R

Rare Diseases

25 items

Takeda Pharmaceutical Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Takeda Pharmaceutical Rank

Latest Takeda Pharmaceutical News

12:30 ET Ulcerative Colitis Market is Expected to Witness Growth at an Accelerated CAGR of 9.5% in the 7MM for the Study Period ...

Oct 26, 2021

Targeted therapies such as Interleukin and JAK inhibitors are making inroads into the Ulcerative Colitis market owing to better clinical profile and also patient convenient dosing News provided by Share this article Share this article LAS VEGAS, Oct. 26, 2021 /PRNewswire/ -- DelveInsight's Ulcerative Colitis Market report offers a detailed comprehension of the Ulcerative Colitis market size by treatment, epidemiology, and emerging therapies. The report also provides an understanding of Ulcerative Colitis market share of the individual therapies, current and forecasted Ulcerative Colitis market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). According to an estimate by DelveInsight, the highest Ulcerative Colitis prevalent cases in the 7MM were found in the United States with 1,008,823 which accounted for nearly 46% of the total 7MM cases, in the year 2020. The market size of Ulcerative Colitis is expected to grow at a CAGR of 9.5% in the 7MM for the study period 2018-2030. Key pharma players working proactively in the Ulcerative Colitis therapeutic market are Gilead Sciences, Galapagos NV, AbbVie, Eli Lilly and Company, Arena Pharmaceuticals, Janssen (Johnson & Johnson), Theravance Biopharma, Landos Biopharma, and several others in the clinical development stage for Ulcerative Colitis will lead to a significant increase in the market size during the forecast period. The key therapies expected to launch in the Ulcerative Colitis market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi (Risankizumab), Mirikizumab (LY-3074828),  Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11, and others. According to DelveInsight analysis, the Ulcerative Colitis market is expected to rise in the coming years due to the entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, increasing prevalence of Ulcerative Colitis, and new biomarkers for diagnosis of Ulcerative Colitis. The major reason behind the Ulcerative Colitis market upsurge would be the improvement in the rise in the number of healthcare spending across the world. For further information on Market Impact by Therapies, Download Ulcerative Colitis Market sample @ Ulcerative Colitis Treatment Landscape  Ulcerative Colitis: Overview Two major types of Inflammatory Bowel Disease (IBD) are Ulcerative Colitis (UC) and Crohn's Disease (CD). Ulcerative Colitis is limited to the colon or large intestine. Approximately 10% of cases of IBD exhibit the features of both Ulcerative Colitis and Crohn's Disease. These are typically known as Indeterminate Colitis (IC). There are different types of Ulcerative Colitis, categorized by the cause of the disease: Ulcerative proctitis, Proctosigmoiditis, Left-sided colitis (also limited or distal colitis), Pancolitis, and Extensive Colitis. There is no single test to diagnose Ulcerative Colitis, instead, the IBD team takes into consideration the symptoms together with the results of Endoscopies, Biopsies, Blood and Stool tests, X-rays, and Imaging Procedures. Ulcerative Colitis Epidemiology Segmentation DelveInsight's analysts indicate that the total diagnosed cases of Ulcerative Colitis  in the 7MM were 1,577,979 in 2020. These cases are expected to rise by 2030, during the forecast period. The Ulcerative Colitis Report  proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into: Total Prevalent Ulcerative Colitis Cases Total Diagnosed Prevalent Ulcerative Colitis Cases Age-Specific Diagnosed Prevalent Cases of Ulcerative Colitis Severity-Specific Diagnosed Prevalent Cases of Ulcerative Colitis Total Treated Ulcerative Colitis Cases Know how Ulcerative Colitis Epidemiological Trends are going to look like in 2030 for the 7 Major Markets by downloading @ Ulcerative Colitis Epidemiological Insights In Ulcerative Colitis treatment, the primary purpose is to help patients properly control their immune systems. A variety of treatment options may help the patient remain in control of the condition and lead a complete and rewarding life, but there is no proven cure for Ulcerative Colitis and flare-ups may recur. Types of medications currently used for the Ulcerative Colitis treatment purpose are Aminosalicylates, Corticosteroids, Immunomodulators, Biologic therapies (Adalimumab, Golimumab, Infliximab, Ustekinumab, Vedolizumab, Janus kinase (JAK) inhibitors, and sphingosine 1-phosphate (S1P) receptor modulators. At times, combination therapy and dietary supplementation are also prescribed. Medications like Aminosalicylates, Corticosteroids, Immunomodulators, Biologic therapies, Janus kinase (JAK) inhibitors, and sphingosine 1-phosphate (S1P) receptor modulators can suppress the inflammation. Ulcerative Colitis pipeline therapies with better clinical profiles include drugs like Risankizumab (ABBV-066), an anti-IL-23 antibody being investigated by AbbVie and Boehringer Ingelheim for the treatment of Ulcerative Colitis. Mirikizumab (LY3074828) is another investigational drug being developed by Eli Lilly and Company to treat Ulcerative Colitis. Few of the novel, oral breakthrough Ulcerative Colitis treatment therapy include Filgotinib by Galapagos, in collaboration with Gilead, TD-1473 by Theravance Biopharma and Janssen, Etrasimod (APD334) discovered by Arena, and BT 11 by Landos Biopharma. Discover more about therapy set to grab substantial Ulcerative Colitis market share @  Ulcerative Colitis Market Scenario Ulcerative Colitis Pipeline Therapies and Key Companies Jyseleca (filgotinib): Gilead Sciences/Galapagos NV Rinvoq (Upadacitinib) & Skyrizi(Risankizumab): AbbVie Mirikizumab (LY-3074828): Eli Lilly and Company Etrasimod: Arena Pharmaceuticals Izencitinib (TD-1473/ JNJ 8398): Theravance Biopharma/Johnson & Johnson BT-11: Landos Biopharma  The current therapeutic landscape of Ulcerative Colitis in the 7MM is driven by several approved therapies. Also, the Ulcerative Colitis market is expected to surge due to factors such as the increasing prevalence of Ulcerative Colitis, entry of novel therapies with better clinical profile and patient convenient RoA, increase in market penetration of targeted/ advanced therapies, new biomarkers for diagnosis of Ulcerative Colitis and also the involvement of digital technology for diagnosis and treatment. A high number of undiagnosed and unreported cases contribute to the lack of awareness of Ulcerative Colitis. The entry of biosimilars in the Ulcerative Colitis Market, insufficient knowledge of the disease, and significant drawbacks of existing therapeutic options may act as certain obstructions in the Ulcerative Colitis market. Study Period: 2018-30 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Companies: Takeda Pharmaceutical, Pfizer, Celgene (Bristol-Myers Squibb), Gilead Sciences, Galapagos NV, AbbVie, Eli Lilly and Company, Arena Pharmaceuticals, Janssen (Johnson & Johnson), Theravance Biopharma, Landos Biopharma Key Ulcerative Colitis Pipeline Therapies: Jyseleca (filgotinib), Rinvoq (Upadacitinib), Skyrizi(Risankizumab), Mirikizumab (LY-3074828),  Etrasimod, Tremfya (Guselkumab), Izencitinib (TD-1473/ JNJ 8398), BT-11 Therapeutic Assessment: Ulcerative Colitis current marketed and emerging therapies Market Dynamics: Ulcerative Colitis market drivers and barriers  Competitive Intelligence Analysis: Porter's five forces, SWOT analysis, PESTLE analysis, Market entry strategies, BCG Matrix, Unmet Needs KOL views Reimbursement Scenario Discover more about the future market share of Ulcerative Colitis treatment therapies @ Ulcerative Colitis Market Future Outlook Table of Contents  Related Reports DelveInsight's, "Ulcerative Colitis (UC)– Pipeline Insight, 2021," report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in Ulcerative Colitis (UC) pipeline landscape which includes companies like AbbVie, Celgene, Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, and several others. DelveInsight's, "Irritable Bowel Syndrome (IBS) - Pipeline Insight, 2021," report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in the Irritable Bowel Syndrome (IBS) pipeline landscape including key companies like Boston Pharmaceuticals, RedHill Biopharma Limited, Takeda, Cosmo Technologies, CinRx Pharma, Rottapharm, SK biopharmaceuticals, Synthetic Biologics, Biomica, and various others. DelveInsight's, "Crohn's Disease – Pipeline Insight, 2021," report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn's Disease pipeline landscape, which includes key companies like Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, and many others. DelveInsight's 'Chronic pancreatitis (CP) - Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the disease, current treatment practice/algorithm, market drivers, market barriers, unmet needs, and key companies involved like Aptalis Pharma, Digestive Care Inc, Kangen Pharmaceuticals, AzurRx BioPharma, and several others. DelveInsight's 'Eosinophilic Esophagitis (EoE)– Market Insights, Epidemiology, and Market Forecast—2030' report delivers an in-depth understanding of the disease, current treatment practice/algorithm, market drivers, market barriers, unmet needs, and key companies involved like Dr Falk Pharma GmbH, Takeda, Regeneron Pharmaceuticals/Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Arena Pharmaceutical, GlaxoSmithKline and others. DelveInsight's 'Chronic Venous Ulceration (CVU) - Market Insights, Epidemiology and Market Forecast– 2030' report delivers an in-depth understanding of the CVU, historical and forecasted epidemiology, market drivers, market barriers, and key companies involved like Merck, Bristol-Myers Squibb, Eli Lilly, Taiho Oncology, Hutchison Medipharma Ltd, G1 Therapeutics, Isofol Medical, AB Science, Seagen, Effector Therapeutics, and many more.

Takeda Pharmaceutical Investments

25 Investments

Takeda Pharmaceutical has made 25 investments. Their latest investment was in Adaptate Biotherapeutics as part of their Series A on April 4, 2021.

CBI Logo

Takeda Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/20/2021

Series A

Adaptate Biotherapeutics

$18M

Yes

2

4/1/2021

Seed VC

Orizuru Therapeutics

$9.07M

Yes

4

10/6/2020

Seed VC

xFOREST Therapeutics

Yes

2

6/25/2020

Series E

Subscribe to see more

$99M

Subscribe to see more

10

5/20/2020

Series C - IV

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/20/2021

4/1/2021

10/6/2020

6/25/2020

5/20/2020

Round

Series A

Seed VC

Seed VC

Series E

Series C - IV

Company

Adaptate Biotherapeutics

Orizuru Therapeutics

xFOREST Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$18M

$9.07M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

4

2

10

10

Takeda Pharmaceutical Portfolio Exits

9 Portfolio Exits

Takeda Pharmaceutical has 9 portfolio exits. Their latest portfolio exit was AmWell on September 17, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/17/2020

IPO

$991

11

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

9/17/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

11

10

10

10

10

Takeda Pharmaceutical Acquisitions

22 Acquisitions

Takeda Pharmaceutical acquired 22 companies. Their latest acquisition was HilleVax on July 31, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/31/2021

Spinoff / Spinout

$135M

Spinoff / Spinout

1

3/9/2021

Partnership

$991

$56M

Acquired

9

4/16/2020

Acquired

1

2/26/2020

Corporate Minority

Subscribe to see more

$991

$99M

Subscribe to see more

10

4/25/2018

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

7/31/2021

3/9/2021

4/16/2020

2/26/2020

4/25/2018

Investment Stage

Spinoff / Spinout

Partnership

Corporate Minority

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$135M

$56M

$99M

$99M

Note

Spinoff / Spinout

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

1

9

1

10

10

Takeda Pharmaceutical Partners & Customers

10 Partners and customers

Takeda Pharmaceutical has 10 strategic partners and customers. Takeda Pharmaceutical recently partnered with Immusoft on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/13/2021

Partner

Immusoft

United States

Takeda to Work With Immusoft in $900 Million Rare-Disease Deal

Takeda Pharmaceutical Co. has options to exclusively license programs at the pre-clinical stage , and Immusoft is eligible for tiered royalties on products that come out of the partnership .

1

10/12/2021

Licensor

Poseida Therapeutics

United States

07:00 ET Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies

Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties , which include , without limitation , the fact that the collaboration agreement with Takeda Pharmaceutical Company Limited may be terminated early , the fact that Poseida Therapeutics , Inc. will have limited control over the efforts and resources that Takeda Pharmaceutical Company Limited devotes to advancing development programs under the collaboration agreement , risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry , the fact that future preclinical and clinical results could be inconsistent with results observed to date and the other risks described in Poseida Therapeutics , Inc. 's filings with the Securities and Exchange Commission .

2

10/4/2021

Licensor

Selecta Biosciences

United States

Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for Patients with Lysosomal Storage Disorders

04 , 2021 -- Selecta Biosciences , Inc. , a biotechnology company leveraging its clinically validated ImmTOR ™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses , today announced that it has entered into a strategic licensing agreement with Takeda Pharmaceutical Company Limited to develop targeted , next-generation gene therapies for two indications within the field of lysosomal storage disorders .

1

9/22/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

9/21/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/13/2021

10/12/2021

10/4/2021

9/22/2021

9/21/2021

Type

Partner

Licensor

Licensor

Partner

Licensor

Business Partner

Immusoft

Poseida Therapeutics

Selecta Biosciences

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

Takeda to Work With Immusoft in $900 Million Rare-Disease Deal

Takeda Pharmaceutical Co. has options to exclusively license programs at the pre-clinical stage , and Immusoft is eligible for tiered royalties on products that come out of the partnership .

07:00 ET Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies

Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties , which include , without limitation , the fact that the collaboration agreement with Takeda Pharmaceutical Company Limited may be terminated early , the fact that Poseida Therapeutics , Inc. will have limited control over the efforts and resources that Takeda Pharmaceutical Company Limited devotes to advancing development programs under the collaboration agreement , risks and uncertainties associated with development and regulatory approval of novel product candidates in the biopharmaceutical industry , the fact that future preclinical and clinical results could be inconsistent with results observed to date and the other risks described in Poseida Therapeutics , Inc. 's filings with the Securities and Exchange Commission .

Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for Patients with Lysosomal Storage Disorders

04 , 2021 -- Selecta Biosciences , Inc. , a biotechnology company leveraging its clinically validated ImmTOR ™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses , today announced that it has entered into a strategic licensing agreement with Takeda Pharmaceutical Company Limited to develop targeted , next-generation gene therapies for two indications within the field of lysosomal storage disorders .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

Takeda Pharmaceutical Service Providers

1 Service Provider

Takeda Pharmaceutical has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Takeda Pharmaceutical Team

21 Team Members

Takeda Pharmaceutical has 21 team members, including current Chief Executive Officer, President, Yasuchika Hasegawa.

Name

Work History

Title

Status

Yasuchika Hasegawa

Chief Executive Officer, President

Current

Frank Morich

Chief Executive Officer

Current

Jeremy G Chadwick

Senior Vice President

Current

Daniel Curran

Senior Vice President

Current

Thom K.

dRx Capital, Cambia Health Solutions, Northwestern Medicine, and Adams Street Partners

Investment Partner

Current

Name

Yasuchika Hasegawa

Frank Morich

Jeremy G Chadwick

Daniel Curran

Thom K.

Work History

dRx Capital, Cambia Health Solutions, Northwestern Medicine, and Adams Street Partners

Title

Chief Executive Officer, President

Chief Executive Officer

Senior Vice President

Senior Vice President

Investment Partner

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.